0 139

Cited 0 times in

Clinical utility of quantitative immunoassays and surrogate virus neutralization tests for predicting neutralizing activity against the SARS-CoV-2 Omicron BA.1 and BA.5 variants

DC Field Value Language
dc.contributor.author김용찬-
dc.contributor.author박윤수-
dc.contributor.author송영구-
dc.contributor.author안진영-
dc.contributor.author이경화-
dc.contributor.author최준용-
dc.date.accessioned2024-01-16T01:55:23Z-
dc.date.available2024-01-16T01:55:23Z-
dc.date.issued2023-12-
dc.identifier.issn0146-6615-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/197791-
dc.description.abstractDeveloping new antibody assays for emerging SARS-CoV-2 variants is challenging. SARS-CoV-2 surrogate virus neutralization tests (sVNT) targeting Omicron BA.1 and BA.5 have been devised, but their performance needs to be validated in comparison with quantitative immunoassays. First, using 1749 PRNT-positive sera, we noticed that log-transformed optical density (OD) ratio of wild-type (WT) sVNT exhibited better titer-correlation with plaque reduction neutralization test (PRNT) than % inhibition value. Second, we tried 798 dilutional titration tests with 103 sera, but nonlinear correlation between OD ratio and antibody concentration limited titration of sVNT. Third, the titer-correlations of two sVNT kits for BA.1 and two quantitative immunoassays for WT were evaluated with BA.1 and BA.5 PRNT. All tested kits exhibited a linear correlation with PRNT titers, but the sVNT kits exhibited high false-negative rates (cPass-BA.1 kit, 45.4% for BA.1 and 44.2% for BA.5; STANDARD F-BA.1 kit, 1.9% for BA.1 and 2.2% for BA.5), while quantitative immunoassays showed 100% sensitivity. Linear mixed-effects model suggested superior titer-correlation with PRNT for quantitative immunoassays compared to sVNT kits. Taken together, the use of quantitative immunoassays for WT, rather than rapid development of new kits, would be practical for predicting neutralizing activities against emerging new variants.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherWiley-Liss-
dc.relation.isPartOfJOURNAL OF MEDICAL VIROLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAntibodies, Neutralizing-
dc.subject.MESHAntibodies, Viral-
dc.subject.MESHCOVID-19* / diagnosis-
dc.subject.MESHHumans-
dc.subject.MESHImmunoassay-
dc.subject.MESHNeutralization Tests-
dc.subject.MESHSARS-CoV-2* / genetics-
dc.titleClinical utility of quantitative immunoassays and surrogate virus neutralization tests for predicting neutralizing activity against the SARS-CoV-2 Omicron BA.1 and BA.5 variants-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorBeomki Lee-
dc.contributor.googleauthorJae-Hoon Ko-
dc.contributor.googleauthorYong Chan Kim-
dc.contributor.googleauthorJin Yang Baek-
dc.contributor.googleauthorYoon Soo Park-
dc.contributor.googleauthorKyoung-Ho Song-
dc.contributor.googleauthorEu Suk Kim-
dc.contributor.googleauthorKyoung Hwa Lee-
dc.contributor.googleauthorYoung Goo Song-
dc.contributor.googleauthorJin Young Ahn-
dc.contributor.googleauthorJun Yong Choi-
dc.contributor.googleauthorWon Suk Choi-
dc.contributor.googleauthorSeongman Bae-
dc.contributor.googleauthorSung-Han Kim-
dc.contributor.googleauthorHye Won Jeong-
dc.contributor.googleauthorYoung Jae Lee-
dc.contributor.googleauthorHye-Jin Kim-
dc.contributor.googleauthorJu-Yeon Choi-
dc.contributor.googleauthorByoungguk Kim-
dc.contributor.googleauthorShin-Woo Kim-
dc.contributor.googleauthorKi Tae Kwon-
dc.contributor.googleauthorKyong Ran Peck-
dc.contributor.googleauthorEun-Suk Kang-
dc.identifier.doi10.1002/jmv.29329-
dc.contributor.localIdA00752-
dc.contributor.localIdA01598-
dc.contributor.localIdA02037-
dc.contributor.localIdA02267-
dc.contributor.localIdA04620-
dc.contributor.localIdA04191-
dc.relation.journalcodeJ01587-
dc.identifier.eissn1096-9071-
dc.identifier.pmid38140877-
dc.identifier.urlhttps://onlinelibrary.wiley.com/doi/10.1002/jmv.29329-
dc.subject.keywordCOVID-19-
dc.subject.keywordSARS-CoV-2 variants-
dc.subject.keywordimmunoassay-
dc.subject.keywordneutralizing antibodies-
dc.contributor.alternativeNameKim, Yong Chan-
dc.contributor.affiliatedAuthor김용찬-
dc.contributor.affiliatedAuthor박윤수-
dc.contributor.affiliatedAuthor송영구-
dc.contributor.affiliatedAuthor안진영-
dc.contributor.affiliatedAuthor이경화-
dc.contributor.affiliatedAuthor최준용-
dc.citation.volume95-
dc.citation.number12-
dc.citation.startPagee29329-
dc.identifier.bibliographicCitationJOURNAL OF MEDICAL VIROLOGY, Vol.95(12) : e29329, 2023-12-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.